Login to Your Account

Santarus Makes Phase III HAE, Pharming for Harvest in Acute

By Randy Osborne and Cormac Sheridan
Staff Writers

Thursday, November 8, 2012

Poised to wade into a crowded field of drugs for hereditary angioedema (HAE), Santarus Inc. and partner Pharming Group NV said the pivotal Phase III study with the C1 esterase inhibitor Ruconest for acute HAE attacks met the primary endpoint of time to beginning of symptom relief.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription